Cross-Clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA

Journal of Virology

Volumn 85, Issue 19, 2011, Pages 9887-9898

  Zolla Pazner, Susan ^a,b   Kong, X P ^b   Jiang, Xunqing ^b   Cardozo, Timothy ^b   Nádas, Arthur ^b   Cohen, Sandra ^b   Totrov, Maxim ^c   Seaman, Michael S ^d   Wang, Shixia ^e   Lu, Shan ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOLSOFT LLC   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CHOLERA TOXIN B SUBUNIT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PROLINE; SCAFFOLD PROTEIN; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLADISTICS; CODON; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS PRESENTATION; CRYSTAL STRUCTURE; ENVELOPE GENE; EPITOPE MAPPING; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN MOTIF; RABBIT; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; IMMUNIZATION, SECONDARY; RABBITS; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 80053952246     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05086-11     Document Type: Article

References (74)

1. Agarwal, A., C. E. Hioe, J. Swetnam, S. Zolla-Pazner, and T. Cardozo. 7 January 2011. Quantitative assessment of masking of neutralization epitopes in HIV-1. Vaccine [Epub ahead of print.] doi:10.1016/j.vaccine.2010.12.052.
2. Alam, S. M., et al. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
3. Almond, D., et al. 2010. Structural conservation predominates over sequence variability in the crown of HIV-1'S V3 loop. AIDS Res. Hum. Retroviruses 26:717-723.
4. Andrus, L., et al. 1998. Passive immunization with a human immunodeficiency virus type-1 neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant. J. Infect. Dis. 177:889-897.
5. Backstrom, M., J. Holmgren, F. Schodel, and M. Lebens. 1995. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli. Gene 165:163-171.
6. Backstrom, M., M. Lebens, F. Schodel, and J. Holmgren. 1994. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene 149:211-217.
7. Barnett, S. W., et al. 2010. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J. Virol. 84:5975-5985.
8. Beddows, S., et al. 2005. Evaluating the immunogenicity of a disulfidestabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79:8812-8827.
9. Belshe, R. B., et al. 1994. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA 272:475-480.
10. Berman, P. W., et al. 1994. Comparison of the immune response to recombinant gp120 in humans and chimpanzees. AIDS 8:591-601.
11. Bianchi, E., et al. 2010. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc. Natl. Acad. Sci. U. S. A. 107:10655-10660.
12. Binley, J. M., et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
13. Burke, V., et al. 2009. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 monoclonal antibodies: implications for design of V3-based immunogens. Structure 17:1538-1546.
14. Cardozo, T., et al. 2009. Worldwide distribution of neutralizing 447-52D and 2219 antibody epitopes in HIV-1. AIDS Res. Hum. Retroviruses 25:441-450.
15. Coeffier, E., et al. 2000. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 19:684-693.
16. Correia, B. E., et al. 2010. Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18:1116-1126.
17. Dennison, S. M., et al. 2011. Non-neutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipid and protein autoantigens. J. Virol. 85:1340-1347.
18. Dhillon, A. K., et al. 2008. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta Crystallogr. D Biol. Crystallogr. 64:792-802.
19. Eckhart, L., et al. 1996. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 77:2001-2008.
20. Eda, Y., et al. 2006. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80:5563-5570.
21. Emini, E. A., et al. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730.
22. Fenyo, E. M., et al. 2009. International Network for Comparison of HIV Neutralization Assays: the NeutNet Report. PLoS One 4:e4505.
23. Forthal, D. N., P. B. Gilbert, G. Landucci, and T. Phan. 2007. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J. Immunol. 178:6596-6603.
24. Gauduin, M. C., J. T. Safrit, R. Weir, M. S. Fung, and R. A. Koup. 1995. Preand postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J. Infect. Dis. 171:1203-1209.
25. Gilbert, P., et al. 2010. Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202:595-605.
26. Gilbert, P. B., et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191:666-677.
27. Gorny, M. K., et al. 2004. The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol. 78:2394-2404.
28. Gorny, M. K., et al. 2009. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 46:917-926.
29. Gorny, M. K., et al. 2002. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J. Virol. 76:9035-9045.
30. Gorny, M. K., et al. 2006. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of HIV-1. J. Virol. 80:6865-6872.
31. Guenaga, J., et al. 2011. Heterologous epitope-scaffold prime: boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant. PLoS One 6:e16074.
32. Haigwood, N. L., et al. 1992. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J. Virol. 66:172-182.
33. Hartley, O., P. J. Klasse, Q. J. Sattentau, and J. P. Moore. 2005. V3: HIV's switch-hitter. AIDS Res. Hum. Retroviruses 21:171-189.
34. Hioe, C. E., et al. 2010. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 5:e10254.
35. Huang, Y., P. B. Gilbert, D. C. Montefiori, and S. G. Self. 2009. Simultaneous evaluation of the magnitude and breadth of a left and right censored multivariate response, with application to HIV vaccine development. Stat. Biopharm. Res. 1:81-91.
36. Jiang, X., et al. 2010. Conserved structural elements in the V3 crown of HIV-1 GP120. Nat. Struct. Mol. Biol. 17:955-961.
37. Kang, Y. K., et al. 2009. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 27:5120-5132.
38. Kim, J. H., S. Rerks-Ngarm, J. L. Excler, and N. L. Michael. 2010. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS 5:428-434.
39. Kwong, P. D., et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420:678-682.
40. Lambert, J. S., et al. 1997. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. J. Infect. Dis. 175:283-291.
41. Law, M., R. M. Cardoso, I. A. Wilson, and D. R. Burton. 2007. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J. Virol. 81:4272-4285.
42. Li, M., et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccineelicited neutralizing antibodies. J. Virol. 79:10108-10125.
43. Li, M., et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80:11776-11790.
44. Lu, S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21:346-351.
45. Mascola, J. R., et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
46. Morner, A., et al. 2009. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J. Virol. 83:540-551.
47. Moseri, A., et al. 2010. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120. Virology 401:293-304.
48. Muster, T., et al. 1994. Cross-neutralizing antibodies against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68:4031-4034.
49. Nkolola, J. P., et al. 2010. Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs. J. Virol. 84:3270-3279.
50. Ofek, G., et al. 2010. Elicitation of structure-specific antibodies by epitope scaffolds. Proc. Natl. Acad. Sci. U. S. A. 107:17880-17887.
51. Ofek, G., et al. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737.
52. Pitisuttithum, P., et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-1671.
53. Saphire, E. O., et al. 2007. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J. Mol. Biol. 369:696-709.
54. Sather, D. N., et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
55. Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
56. Seaman, M. S., et al. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84: 1439-1452.
57. Selvarajah, S., et al. 2005. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79:12148-12163.
58. Selvarajah, S., et al. 2008. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res. Hum. Retroviruses 24:301-314.
59. Smith, D. H., et al. 2010. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. PLoS One 5:e12076.
60. Stanfield, R. L., M. K. Gorny, C. Williams, S. Zolla-Pazner, and I. A. Wilson. 2004. Structural rationale for the broad neutralization of HIV-1 by human antibody 447-52D. Structure 12:193-204.
61. Stanfield, R. L., M. K. Gorny, S. Zolla-Pazner, and I. A. Wilson. 2006. Crystal structures of HIV-1 neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80:6093-6105.
62. Stover, J., L. Bollinger, R. Hecht, C. Williams, and E. Roca. 2007. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Aff. (Millwood) 26:1147-1158.
63. Sundling, C., et al. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207:2003-2017.
64. Swetnam, J., E. Shmelkov, S. Zolla-Pazner, and T. Cardozo. 2010. Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes. PLoS One 5:e15994.
65. Tomaras, G. D., and B. F. Haynes. 2010. Strategies for eliciting HIV-1 inhibitory antibodies. Curr. Opin. HIV AIDS 5:421-427.
66. Totrov, M., et al. 2010. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Virology 405:513-523.
67. Vaine, M., et al. 2011. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J. Virol. 85:4927-4936.
68. Verrier, F., A. Nadas, M. K. Gorny, and S. Zolla-Pazner. 2001. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J. Virol. 75:9177-9186.
69. Willey, R., M. C. Nason, Y. Nishimura, D. A. Follmann, and M. A. Martin. 2010. Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res. Hum. Retroviruses 26:89-98.
70. Zhang, P. F., et al. 2007. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. U. S. A. 104:10193-10198.
71. Zolla-Pazner, S., and T. Cardozo. 2010. Structure-function relationships of HIV-1 envelope sequence-variable regions provide a paradigm for vaccine design. Nat. Rev. Immunol. 10:527-535.
72. Zolla-Pazner, S., et al. 2009. Cross-clade neutralizing antibodies against HIVI-1 induced in rabbits by focusing the immune response on a neutralizing epitope. Virology 392:82-93.
73. Zolla-Pazner, S., et al. 2008. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372:233-246.
74. Zwick, M. B., et al. 2001. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J. Virol. 75:12198-12208.